Senbo Peer Comparison

BSE: 532021

₹7.00

₹-0.04 (-0.63%)

As on 01-Aug-2019IST

Market cap

₹8 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

-0.4

Div. Yield

0 %

Edit

	Senbo	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	8	33,911	29,031	28,149	27,692
Revenue (₹ Cr)	--	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	-1.04	414.00	288.22	387.35	-371.81
Net Margin (%)	-3,714.29	11.23	14.79	26.01	-3.93
RoE (%)	--	8.38	29.77	25.18	-3.85
Price to Earnings	--	82.91	100.73	72.88	--
Price-To-Book	-0.42	6.74	21.63	16.31	3.46

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Senbo	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	0.00	3,565.84	153.79	238.51	--
Total Income	0.07	3,586.86	160.15	238.90	--
Total Expenditure	0.83	3,604.32	122.14	196.43	--
EBITDA	-0.83	-38.48	31.65	42.08	--
Depreciation	0.15	163.95	8.26	2.60	--
EBIT	-0.98	-202.43	23.39	39.48	--
Interest	0.08	265.14	2.61	4.75	--
Other Income	0.07	21.02	6.36	0.38	--
Exceptional Items	--	-358.19	--	--	--
Profit before Tax	-0.98	-446.55	27.14	35.11	--
Provision for Tax	0.04	-134.76	8.71	11.82	--
Profit after Tax	-0.98	-311.79	18.43	23.30	--

Liabilities (₹ Cr)

	Senbo	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	-18.58	2,674.80	196.86	82.22	--
Minority Interest	--	329.83	--	--	--
Non-Current Liabilities	19.18	1,702.75	30.75	25.37	--
Current Liabilities	1.64	2,863.66	68.83	105.56	--
Total Liabilities	2.24	7,813.24	296.44	213.15	--

Assets (₹ Cr)

	Senbo	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	2.17	4,756.39	131.06	85.41	--
Current Assets	0.06	2,814.65	165.38	124.10	--
Total Assets	2.24	7,813.24	296.44	213.15	--
Total Debt*	19.19	3,374.60	49.52	53.91	--
Net Current Assets	-1.57	-49.01	96.56	18.54	--
Contingent Liabilities	--	473.19	0.48	0.08	--

Cashflow (₹ Cr)

	Senbo	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	-2.49	183.32	-13.77	14.84	--
Cash Flow from Investing Activities	2.55	94.57	4.25	-20.87	--
Cash from Financing Activities	-0.06	-776.45	16.43	5.62	--
Net Cash Inflow / Outflow	0.00	-498.56	6.91	-0.41	--

Ratios

Profitability Ratios

	Senbo	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	-82.72	-2.87	13.09	34.33	--
ROE (%)	0.00	-11.43	9.82	34.64	--
ROA (%)	-38.59	-4.01	7.04	12.64	--
EBIT Margin (%)	--	-0.49	24.71	17.80	--
Net Margin (%)	-1,372.03	-8.69	11.51	9.75	--
Cash Profit Margin (%)	--	-4.15	17.35	10.86	--

Growth Ratios

	Senbo	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	--	-9.43	135.95	26.72	--
EBIT Growth (%)	-1,591.99	-114.30	326.10	26.85	--
Net Profit Growth (%)	-319.13	53.24	8,583.73	25.95	--
EPS Growth (%)	-319.13	68.03	8,583.73	25.51	--
Book Value Growth (%)	-5.59	-6.14	10.33	40.52	--

Valuation Ratios

	Senbo	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	0.00	0.00	0.00	0.00	--
Price / Book Value	0.00	1.86	0.00	0.00	--
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	-39.43	-448.40	1.14	1.51	--
Market Cap (₹ Cr)	--	4,903.12	0.00	0.00	--

Solvency Ratios

	Senbo	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	-1.03	1.28	0.25	0.69	--
Short term debt to equity ratio	0.00	0.21	0.07	0.32	--
Current Ratio	0.04	0.98	2.40	1.18	--
Quick Ratio	0.04	0.70	2.12	0.81	--
Interest Coverage	-12.09	-0.68	11.39	8.39	--

Operating Efficiency Ratios

	Senbo	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	--	35.73	54.90	31.90	--
Asset Turnover	0.00	0.46	0.59	1.29	--
Receivable days	--	114.46	144.39	96.45	--
Inventory Days	--	85.73	39.59	50.55	--
Payable days	--	160.83	158.53	142.81	--
Cash Conversion Cycle	--	39.36	25.45	4.19	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly